BioAtla, Inc.

BioAtla, Inc. has filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled to be held virtually on July 16, 2026. Stockholders of record as of May 18, 2026, will be able to vote on the election of directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm, and an advisory vote on executive compensation. The company also disclosed a 50-for-1 share consolidation that occurred on April 6, 2026, with all historical share and per share amounts adjusted accordingly. The board of directors recommends a vote 'FOR' all proposed items.

BioAtla, Inc. reported a net loss of $(6.34) million for Q1 2026, a significant improvement from $(15.33) million in Q1 2025, driven by reduced operating expenses. However, the company issued a going concern warning, citing cumulative operating losses and negative cash flows. In response, BioAtla initiated a formal process to explore strategic options and implemented a 70% workforce reduction.

BioAtla, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, to include previously omitted Part III information covering corporate governance, executive compensation, and related matters. Additionally, the company announced a 50-for-1 share consolidation of its common stock, effective April 6, 2026, with all share and per share amounts retroactively adjusted in the amendment. New certifications from the principal executive and financial officers were also filed.

BioAtla, Inc. filed an Amendment No. 1 on Form 10-K/A to its Annual Report for the fiscal year ended December 31, 2025. The amendment primarily includes information required by Part III of Form 10-K, which was previously omitted, covering directors, executive officers, and corporate governance. It also updates the cover page and includes new certifications. Additionally, the company effected a 50-for-1 share consolidation on April 6, 2026, retroactively adjusting all share and per share amounts and equity awards.

BioAtla, Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The amendment primarily includes information required by Part III of Form 10-K, covering directors, executive officers, corporate governance, executive compensation, and related matters, which was previously omitted. Additionally, the company disclosed a 50-for-1 share consolidation effective April 6, 2026, with all share and per share amounts retroactively adjusted. New certifications from the principal executive and financial officers were also filed.